Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRATED BIOPHARMA INCinpb.ob · Entity 8227 | Director | November 18, 2016 | November 22, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRATED BIOPHARMA INC
Report date November 18, 2016 · Filed November 22, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2026-11-18 | Direct | 50,000 |
Reported balance
After 2016-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-18 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests 5/12ths (20,831) on grant date (November 18, 2016) and in 7 monthly installments for the remaining 7/12ths (29,169) beginning on December 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests 5/12ths (20,831) on grant date (November 18, 2016) and in 7 monthly installments for the remaining 7/12ths (29,169) beginning on December 1, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2016 Filed Nov 22, 2016 21:37 UTC | INTEGRATED BIOPHARMA INC inpb.ob · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001644435-16-000002 · primary_doc.xml · derivative · entry 1 LAPLACA JOSEPH · CIK 0001644435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-11-18 F1 · derivative.exercise_date: The option vests 5/12ths (20,831) on grant date (November 18, 2016) and in 7 monthly installments for the remaining 7/12ths (29,169) beginning on December 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.